Orphazyme A/S EBIT

The latest EBIT for ORPH is $-36M as of June 2024. That compares with $-850M in the prior-year period — up 95.7% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Orphazyme A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, ORPH's EBIT moved from $-850M to $-36M — a 95.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Orphazyme A/S's operating scale or balance-sheet position.

Against Healthcare companies, ORPH currently prints $-36M for EBIT, while the sector average sits near $23B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Orphazyme A/S's growth, margins, and balance sheet.

A EBIT figure of $-36M for ORPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ORPH's EBIT ($-36M), review year-over-year change from $-850M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.